GENE ONLINE|News &
Opinion
Blog

Business Model and Financial Strategy DecisionsLicensing, M&A, partnering, scaling-up, IPO and m

by GeneOnline
Share To
 
 

The pathways are many, the risks are varied, but the choices made early on will be critical to the future success of a growing biotech company. In this session, we have invited industry veterans and heavyweight speakers to advise on making important decisions around business model development and strategy.

Swimming with Sharks: Early Stage Biotechnology Business Models and Financing Strategies

Dr. Carter will give a talk about bioindustry development cycles and introducing the challenges and opportunities for all early-stage companies.

 

Building a Biotechnology Company through Collaboration, Licensing and M&A

Mr. Grady will address why AstraZeneca set up an innovation center in China while most western big pharma retreated. What strategies, pipelines, or disease areas so far and what can we expect from these strategies?

 

Dr. Li is a Venture Partner with Lilly Asia Ventures. He was most recently Executive VP and Global Head of Business Development at BeiGene; prior to that, he was VP of Business Development and Licensing at Merck and Executive Director of External R&D at Amgen. With over 21 years of industry experience, he will be sharing his investment strategy and insights.

 

Dr. McCracken will share his insight regarding Genentech has leveraged academic collaborations, in-licensing, out-licensing, and M&A to discover and bring its innovative medicines to patients.

 

Session organizer:

Online @ BIO Asia-Taiwan, July 23.
15:40-17:10 Taipei Time

 
Don’t miss your chance to join thousands of bioindustry professionals from Asia and around the world at BIO Asia–Taiwan 2020 Online + Live!
BIO Asia-Taiwan 2020 Secretariat

[email protected] | www.bioasiataiwan.com | +886-2-7700-3883

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Investment Summit Highlights: Advancements in Therapeutics & Pharmaceuticals
2024-08-02
BIO Asia-Taiwan Kicks Off with the Latest Cell and Gene Therapy Developments
2024-07-24
BIO Asia-Taiwan 2022: Looking for the Exit; Startup Considerations and Strategies
2022-07-28
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top